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Introduction
The first rank of malignancy in women is breast 
carcinoma. New breast carcinoma cases have 
been recorded about were 2.1 million in 2018. According to the GLOBOCAN, the mortality 
rate of breast carcinoma in the world has been 
predicted as many as 626,000 cases in 2018, and it is a major cause of death in malignant disease.1Mammography is the radiological modality 
of choice for screening and diagnosis of breast carcinoma, with a sensitivity of 75–85% and 
a specificity of 90%.2 One mammographic anomaly that is easily detected, and often the 
earliest signs of malignant breast disease is a 
very small calcium deposit in breast soft tissue 
known as micro calcification (MC). Although MC 
is also associated with benign conditions such 
as secretory disease and fat necrosis, about 
40% of breast cancer are often accompanied by MC. The MC size is less than 1 mm and the MC is the only mammographic feature that shows the presence of a tumor and its ppresence is a 
major risk factor for breast cancer. A previous study has found that MC in malignant lesions 
tends to be smaller, more numerous, and occur in the milk ducts and other related structures in 
the breast and follow the anatomy of the duct.3 
There are several possible causes of calcification, including the development of scar tissue after 
biopsy or surgery, fluid accumulation, epithelial 
proliferation, tissue necrosis, and inflammation. 
Inflammation has been previously linked to 
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Abstract
Background: Breast carcinoma shows over-expression of Human Epidermal Growth Factor Receptor 
2 (HER-2) in 18 to 20% of the cases. This type of cancer is very progressive and has a poor prognosis. 
This study aimed to determine the association between the calcification on mammography with HER-2 
expression in breast carcinoma as a marker of breast carcinoma aggressiveness. 
Methods: This was an analytic observational study with a case-control design. Patients with breast carcinoma at the Department of Radiology and Department of Anatomical Pathology of Dr. Hasan 
Sadikin General Hospital Bandung from July–September 2019 were enrolled in this study. Samples were 
consecutively collected. The association of calcification on mammography and HER2 expression was analyzed using the Chi-square test. 
Result: In total, 40 patients were included, consisting of 20 individuals with HER-2 positive and 20 
individuals with HER-2 negative. The youngest was 40 years old and the oldest was 73 years old. 
Statistical test results showed that there was a significant association between calcifications in 
mammography and HER-2 expression (p-value = 0.0001, OR 13.22; 95% CI 2.7–62.6).
Conclusions: There is a significant association between calcification on mammography and HER-2 
expression in breast carcinoma, suggesting that positive calcification mammography was 13.22 times 
higher in patients with HER-2 positive compared to patients with negative calcifications.
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poor breast cancer prognosis and disease 
progression, possibly due to the recruitment of macrophages that promote tumor growth and proteinases which decrease the extracellular 
matrix. Suspicious morphology is calcification 
of mammography that can be suspected in the 
direction of malignancy can be classified into 
Breast Imaging Reporting and Data System (BI-
RADS) 4B or 4C and BI-RADS 5 for fine linear 
branching calcification.4–6
The immunohistochemical (IHC) profile 
examinations have been used extensively 
as a basis for selecting hormonal therapy and targeting therapy. Examination of IHC can detect cancer cell hormone receptor 
types, namely estrogen receptor (ER) and 
progesterone receptor (PR), as well as expression of human epidermal growth factor 
receptor-2 (HER-2). HER-2 is a protooncogene 
that belongs to the epidermal growth factor 
receptor (EGFR) group. Amplification of HER-2 is considered a poor independent 
prognostic factor in invasive breast carcinoma 
and has been associated with changes in clinical response to systemic treatment of 
breast cancer such as with chemotherapy 
and antiestrogens. HER-2 is positive in about 
18–20% of breast cancers. Positive HER-2 can 
be classified as HER-2 type (enriched) if HER-2 is positive and estrogenic and progesterone receptors are negative. HER2-positive luminal 
B if HER-2 is positive and one or both hormones 
are positive, while negative HER-2 can be 
classified as luminal A if HER-2 is negative 
and one or both of the hormone receptors is positive and low Ki-67 and HER2-negative 
Luminal B if HER-2 is negative and one or both of the hormone receptors is positive and high 
Ki- 67 and Basal-like (Triple-negative) if HER-
2 and both hormone receptors are negative. Overexpression of HER-2 increases the 
‘survival’ of breast cancer cells by increasing cell 
proliferation, inhibiting cell apoptosis (death), 
and increasing angiogenesis by increasing the production of vascular endothelial growth factor. Studies show that there is a correlation 
between calcifications found on mammography 
with HER-2 overexpression in primary breast carcinoma patients compared with patients who did not overexpression of HER-2. 
Amplification of HER-2 is considered as an independent poor prognostic factor in invasive 
breast carcinomas and has been associated with altered clinical responsiveness to systemic 
breast cancer treatment such as chemotherapy and antiestrogens.7–10 The aim of the study 
was to determine the relationship between 
calcification on mammography and HER-2 
expression in breast carcinoma. 
Methods
This study was an observational analytic approach with a case-control study 
design. Subjects over 40 years old with 
preoperative breast carcinoma through histopathological examination had undergone immunohistochemical HER-2 examination. 
The minimum samples number for each group 
is 20 samples. Then the total sample for the 2 
groups is 40 samples divided into 20 subjects 
with positive HER-2 results and 20 subjects 
with negative HER-2 results. All subjects were undergo mammography examination from July 
to September 2019. This study was approved 
by the Ethical Committee of Universitas 
Table 1 Characteristics of Research Subjects Based on Age and IHC Results
Variable n %
Age (years)
     40–60 33 82.5
     >60 years 7 17.5IHC Result     HER-2 type 12 30     HER2-positive Luminal B 8 20     HER2-negative Luminal B 15 37.5     Basal-like /triple- negative 5 12.5     Luminal A - -Total 40 100
Note: IHC= immunohistochemistry
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The mammograms were obtained 
with digital mammography (Metaltronica 
Helianthus type, Italy). Standard craniocaudal 
and lateral views were carried out in all subjects. 
The mammograms of all subjects were blindly 
reviewed by an experienced breast radiologist. 
Mammographic findings were categorized as 
with or without calcifications. 
The HER-2 status was determined by IHC staining of tissue sections with primary 
antibody anti-PD-L1 rabbit monoclonal 
(clone 28-8, cat No. ab205921, Abcam, Inc 
Cambridge, USA)with 1:200 dilution and 
CD133 polyclonal mouse antibody from 
Elabscience (E-AB-16223) USA with 1:100 dilution. Detection was carried through with 
streptavidin-biotin immunoperoxide complex. 
Positive HER-2 if IHC staining +3 (uniform 
membrane coloring and more than 10% 
invasive tumor cells). Negative HER-2 if IHC 
staining 0 (none membrane coloring and less 
than 10% invasive tumor cells) or positive 1 
(weak membrane coloring and more than 10% 
invasive tumor cells). The samples analysis was 
done by a pathologist that was an expert in IHC examination at the Department of Anatomical Pathology Dr. Hasan Sadikin General Hospital. The Chi-square test was used to evaluate 
the association between mammographic 
findings and HER-2 expression in breast 
carcinomas. All statistical tests were two-
sided while the statistical significance of the 
observed difference was set at p<0.05. The 
Odds ratio (OR) value resulted from the Chi-square test was to measure the strength of causal and effect relationships. All data were analyzed using Statistical Package for the 
Social Sciences statistical software (SPSS) 
version 24.0 for windows.
Results 
Most breast cancer patients were aged 40–60 
years (82.5%), and most with HER-2 negative 
luminal B IHC results (37.5%). Characteristics 
of research subjects based on age and IHC 
results in study subjects were presented in 
Table 1).The mammoghrapy result with MC from a patient was shown in Figure 1. Characteristics 
of the study subjects based on the findings 
of calcifications in each molecular subtype were depicted in Figure 2. The relationship 
of calcification on mammography with HER-2 overexpression compared with patients who 
did not overexpress HER-2 in breast carcinoma 
sufferers was shown in Table 2. 
The relationship of calcification on mammography with HER-2 overexpression 
compared with patients who did not in breast carcinoma sufferers. In the positive HER-2 
Figure 1 Mammogram (RMLO) Showing Microcalcifications (Arrow)
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group, patients with positive calcification 
mammography were 17 (85.0%) and 
negative calcifications were 3 (15.0%). In the negative HER-2 group, patients with positive 
calcification mammography were 6 (30.0%) 
and negative calcifications were 14 (70.0%). 
Chi-Square test analysis results obtained a 
p-value of 0.0001, meaning that there was a 
statistically significant relationship between 
calcification in mammography with HER-
2 expression in breast carcinoma. The OR 
was 13.22 (95% CI 2.7-62.6), suggesting that 
positive calcification mammography was 13.22 times higher in positive of HER-2 compared to 
patients with negative calcifications.
Discussion
Our study shows that the most age distribution 
with carcinoma in the breast was the age 
group 40–60 years (82%). This is following the 
literature that the incidence of breast cancer 
increases with age and 95% of cases of breast 
cancer occur in women aged 40 years or more. Breast cancer rarely occurs at a young age of 
less than 40 years.11 The most IHC results from 
this study subjects are HER-2 negative luminal 
B (37%). It was similar to another study that reported the highest incidence is HER-2 
negative luminal B (31%).12 In a prospective study has found that triple negative as the most 
subtypes (23%) followed by HER-2 negative 
luminal B (21%).10
Interestingly, positive calcifications have 
been shown in 15% of subjects with negative 
HER-2 similar to other research (10%).10 
Calcification in subjects with negative HER-2 
is thought to be related to factors other than HER-2 such as hormonal factors. Another study 
has found a relationship between hormonal 
Figure 2 Characteristics of Study Subjects based on the Findings of Calcification in Each 
Molecular Subtype
Table 2 Relationship of Calcification on Mammography with HER-2 Overexpression 
Compared with Did Not Overexpress HER-2 in Patients with Breast Carcinoma.
Mammography
Group
OR 
CI (95%) P-valueHER-2 Positive HER-2 Negative
n=20 n=20
Positive calcification 17 (85.0%) 6 (30.0%) 13.22 0.0001
Negative calcification 3 (15.0%) 14 (70.0%) (2.790–62.670)
Note: Chi -Square test*. Significance value base on p-value <0.05
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receptors which are positive estrogen 
receptor and calcification on mammography.6 
Calcification may have another cause such 
as a history of inflammation and previous tissue necrosis.6 Positive calcifications in the HER-2 negative luminal B and triple negative 
molecular subtypes which are HER-2 negative 
groups may give negative calcification imaging on mammography, with HER-2 
negative luminal B as the most calcifications in the negative HER-2 group. Another study has shown that luminal A, HER-2 negative luminal B and triple negative in the negative 
HER-2 group which provided calcification on mammography with luminal A as the most 
subtypes.10
Negative calcifications in the positive HER-
2 group (15%) may occur in positive HER-2 luminal B as also found in another study that showed samples in the positive HER-2 group 
with negative MC on mammography (20%).10 
Figure 2 shows that the most MC have been found in the HER-2 type, similar to another 
study that the most calcifications in the HER-
2 type subtype have positive calcifications.6,10
 Table 2 has shown a significant relationship 
between calcification on mammography and 
HER-2 expression in breast carcinoma. In this 
study, positive calcifications found (85%) are associated with positive HER-2. Another study 
has shown positive calcifications and positive 
of HER-2 expression in more than 60%.4,10 The 
correlation of calcifications on mammography with HER-2 expression with an OR of 13.22, suggesting that the risk of positive HER-2 on 
positive calcification on mammography is 
13.22 times compared to negative calcification. Another study shows a relationship with a higher OR of 8.1.10The weakness of the study is that there are 
subjects who still have dense fibrogranular 
tissue, although they are over 40 years old. Therefore, the position on mammography 
needs to be improved. Also, some subjects 
have large and hard masses, making it difficult 
to cover by mammography tools.
In conclusion, there is a significant 
relationship between calcification on mammography with HER-2 overexpression 
in breast carcinoma with an OR of 13.22. 
Calcifications detected during mammography 
not only have diagnostic value but it can also predict the choice of therapy.
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